The relative impact of actual and potential rivalry on firm profitability in the pharmaceutical industry

Strategic Management Journal

Volumn 20, Issue 1, 1999, Pages 1-14

  Cool, Karel ^a   Röller, Lars Hendrik ^b   Leleux, Benoit ^c  

^a INSEAD   (France)

^b HUMBOLDT UNIVERSITY   (Germany)

^c BABSON COLLEGE   (United States)

Author keywords

Drug industry; Industry profitability; Market share; Potential competition; Rivalry

Indexed keywords

EID: 0002809836     PISSN: 01432095     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0266(199901)20:1<1::AID-SMJ995>3.0.CO;2-X     Document Type: Article

References (32)

1. Bain, J. (1956). Barriers to New Competition. Harvard University Press, Cambridge, MA.
2. Baumol, W., J. Panzar and R. Willig (1982). Contestable Markets and the Theory of Industry Structure. Harcourt, New York.
3. Bond, R. and D. Lean (1977). Sales Promotion and Product Differentiation in Two Prescription Drug Markets. Federal Trade Commission, Washington, DC.
4. Brooke, P. (1975). Resistant Prices. Council on Economic Priorities, New York.
5. Clarke, R., S. Davis and M. Waterson (June 1984). 'The profitability-concentration relationship: Market power or efficiency', Journal of Industrial Economics, pp. 435-450.
6. Comanor, W. (September 1986). 'The political economy of the pharmaceutical industry', Journal of Economic Literature, pp. 1178-1217.
7. The Competitive Status of the U.S. Pharmaceutical Industry (1983). The Pharmaceutical Panel, Committee on Technology and International Economic and Trade Issues. National Academy Press, Washington, DC.
8. Cool, K. and I. Dierickx (1993). 'Rivalry, strategic groups and firm profitability', Strategic Management Journal, 14(1), pp. 47-59.
9. Cool, K., I. Dierickx and D. Jemison (1989). 'Business strategy, market structure and risk-return relationships: A structural approach', Strategic Management Journal, 10(6), pp. 507-522.
10. Gilbert, R. (1989). 'The role of potential competition in industrial organization', Journal of Economic Perspectives, pp. 107-127.
11. Grabowski, H., J. Vernon and L. G. Thomas (1976). 'The effects of regulatory policy on the incentives to innovate: An international comparative analysis'. In S. Mitchell and E. Link (eds.), Impact of Public Policy on Drug Innovation and Pricing. AEI, Washington, DC, pp. 47-82.
12. Griliches, Z. (1979). 'Issues in assessing the contribution of R&D to productivity growth', Bell Journal of Economics, Spring, pp. 92-116.
13. Effective Patent Life (1993). Memo, Pharmaceutical Manufacturers Association, Washington, DC.
14. Hanson, R. (1980). 'Pharmaceutical development cost by therapeutic categories', University of Rochester GSM, Working Paper #GPB-80-6.
15. Hurdle, G., R. Johnson, A. Joskow, G. Werden and M. Williams (December 1989). 'Concentration, potential entry and performance in the airline industry', Journal of Industrial Economics, pp. 119-139.
16. Hurwitz, M. and R. Caves (October 1988). 'Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals', Journal of Law and Economics, pp. 299-320.
17. Jaffe, A. (December 1986). 'Technological opportunities and spillovers of R&D', American Economic Review, pp. 984-1001.
18. Kwoka, J. (February 1979). 'The effect of market share distribution on industry performance', Review of Economics and Statistics, pp. 351-363.
19. Maddala, G. (1977). Econometrics. McGraw-Hill, New York.
20. Mattison, N., G. Trimble and L. Lasagna (March 1988). 'New drug development in the United States, 1963 through 1984', Clinical Pharmacology and Therapeutics, pp. 15-27.
21. Moore, W. and R. Newman (April 1993). 'Drug formulary restrictions as a cost-containment policy in Medicaid programs', Journal of Law and Economics, pp. 71-97.
22. National Prescription Audit (various years). IMS America. Ambler, PA.
23. New Drug Evaluation Statistical Report, 1985. U.S. Food and Drug Administration, Washington, DC.
24. New Product Index (various years). Paul de Haen International, Englewood, CO.
25. New Product Survey (various years). Paul de Haen International, Englewood, CO.
26. Schwartz, M. and R. Reynolds (June 1983). 'Contestable markets: An uprising in the theory of industry structure: A comment', American Economic Review, pp. 488-490.
27. Shepherd, W. (February 1972). 'The elements of market structure', Review of Economics and Statistics, pp. 25-37.
28. Thomas, L. G. (1990). 'Regulation and firm size: Impact on innovation', Rand Journal of Economics, Winter, pp. 497-517.
29. U.S. Drug Stores and Hospitals Audits (various years). IMS America, Ambler, PA.
30. Wardell, W., M. May and G. Trimble (1982). 'New drug development by United States pharmaceutical firms', Pharmacology and Therapeutics, pp. 407-417.
31. Wardell, W. and L. Sheck (1984). 'Is pharmaceutical innovation declining? Interpreting measures of pharmaceutical innovation and regulatory impact in the U.S.A., 1950-1980'. In B. Lundgren (ed.), Pharmaceutical Economics. Swedish Institute for Health Economics, Lund, pp. 177-189.
32. Wiggins, S. (1984). 'The effect of U.S. pharmaceutical regulation on new introductions'. In B. Lundgren (ed.), Pharmaceutical Economics. Swedish Institute for Health Economics, Lund, pp. 191-205.